Ascendis Pharma ADR had its Relative Strength (RS) Rating upgraded from 79 to 85 Wednesday.
This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against other publicly traded companies.
Decades of market research shows that the stocks that go on to make the biggest gains often have an 80 or better RS Rating as they launch their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Ascendis Pharma ADR is trying to complete a consolidation with a 161.00 buy point. See if the stock can clear the breakout price in heavy trade.
The company showed 0% EPS growth in the latest quarterly report. Sales rose 184%.
The company holds the No. 91 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
